Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Symptomatic Uterine Leiomyomas Clear all
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Elastography (MRE) of Uterine Fibroids

NCT01229826
View directory record Official record
Conditions
Uterine Fibroids
Interventions
MR Elastography
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
View directory record Official record
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

Safety Study of ExAblate for the Treatment of Uterine Fibroids

NCT01142791
View directory record Official record
Conditions
Uterine Fibroids
Interventions
ExAblate
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 4 Interventional

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

NCT00995878
View directory record Official record
Conditions
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
Focused ultrasound (MRgFUS), Uterine artery embolization (UAE)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00683917
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg, Lupron Depot
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Sarasota, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00853567
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, placebo
Drug · Other
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Not applicable Interventional Results available

Embozene Microspheres for Uterine Fibroid Embolization (UFE)

NCT01675011
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Embozene® Microspheres, Embosphere®
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
30 Years to 50 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Albany, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00735553
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

NCT00702702
View directory record Official record
Conditions
Uterine Fibroids, Anemia
Interventions
Proellex 25 mg, Proellex 50 mg, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

NCT00628901
View directory record Official record
Conditions
Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions
Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres
Procedure · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

NCT02227316
View directory record Official record
Conditions
Symptomatic Uterine Fibroids and Adenomyosis
Interventions
IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

NCT02323646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Placebo, Telapristone Acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00882258
View directory record Official record
Conditions
Uterine Fibroids
Interventions
12.5 mg Proellex, 25 mg Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02301897
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone Acetate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

NCT01069120
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
4
States / cities
Boynton Beach, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
View directory record Official record
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids

NCT01285960
View directory record Official record
Conditions
Uterine Fibroids
Interventions
ExAblate Treatment UF V2
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional Results available

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

NCT00737282
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Beverly Hills, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02811159
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Jul 21, 2026, 4:52 PM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

NCT00874302
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
San Diego, California • Sarasota, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids

NCT00874029
View directory record Official record
Conditions
Uterine Fibroids, Uterine Myomas
Interventions
Halt Procedure
Device
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
25 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Jul 21, 2026, 4:52 PM EDT
Recruiting No phase listed Observational

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

NCT05386615
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Body System - Functional
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jul 21, 2026, 4:52 PM EDT